Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Mar 4, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid has hired Michael Bates to be VP of oncology research and development. Bates will be responsible for the company's microRNA program and the development and preclinical evaluation of its oncology testing portfolio.

Bates formerly was VP of clinical research at Monogram Biosciences, which was bought by LabCorp in 2009, where he was responsible for clinical research strategy and running the firm's oncology and virology programs.

Helicos Biosciences said this week that Elisabeth Allison and Robert Higgins have resigned from the firm's board of directors. The single-molecule sequencing technology developer said that their departures were not caused by any disagreement with the company related to operations, policies, or practices.

PharmaDiagnostics has named Sylviane Boucharens to be director of assay development. Boucharens formerly was head of a global compound repository and in vitro screening at Merck MSD's site in Newhouse, Scotland. Before that, she worked in the Immunology Department for Laboratoires Fournier.

The Biotechnology and Biological Sciences Research Council and the Institute for Animal Health (IAH) have appointed John Fazakerley to serve as IAH's new director, starting in June. Fazakerley currently is group leader and a professor of virology at The Roslin Institute in BBSRC's College of Medicine and Veterinary Medicine at the University of Edinburgh. He will take over the position for David Paton, who has been serving as interim director since Martin Shirley retired from the post.

IntegenX said this week that it has appointed Dennis Harris to be the company's chief scientific officer. Harris is a co-founder of IntegenX and has served on the company's board of directors since 2003. He served as CSO of Millipore until December 2010, when the company was acquired by Merck KGaA. Prior to that, he was vice president and CSO at Serologicals, which Millipore acquired in 2006.

Thomas Gallagher has stepped down from his positions as president, COO, and general counsel of Health Discovery Corporation to pursue a new opportunity. The company said this week that Gallagher will soon begin discussions with its board of directors to potentially start a new company that would use a non-exclusive license to HDC's patent portfolio in exchange for a minority ownership stake in the new venture.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.